151 related articles for article (PubMed ID: 27424909)
1. In Vivo Bioluminescent Imaging of ATP-Binding Cassette Transporter-Mediated Efflux at the Blood-Brain Barrier.
Bakhsheshian J; Wei BR; Hall MD; Simpson RM; Gottesman MM
Methods Mol Biol; 2016; 1461():227-39. PubMed ID: 27424909
[TBL] [Abstract][Full Text] [Related]
2. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
Bakhsheshian J; Wei BR; Chang KE; Shukla S; Ambudkar SV; Simpson RM; Gottesman MM; Hall MD
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20801-6. PubMed ID: 24297888
[TBL] [Abstract][Full Text] [Related]
3. ATP-binding cassette transporters modulate both coelenterazine- and D-luciferin-based bioluminescence imaging.
Huang R; Vider J; Serganova I; Blasberg RG
Mol Imaging; 2011 Jun; 10(3):215-26. PubMed ID: 21496450
[TBL] [Abstract][Full Text] [Related]
4. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging.
Zhang Y; Bressler JP; Neal J; Lal B; Bhang HE; Laterra J; Pomper MG
Cancer Res; 2007 Oct; 67(19):9389-97. PubMed ID: 17909048
[TBL] [Abstract][Full Text] [Related]
5. Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier.
Kumar JS; Wei BR; Madigan JP; Simpson RM; Hall MD; Gottesman MM
Sci Rep; 2016 Feb; 6():20418. PubMed ID: 26853103
[TBL] [Abstract][Full Text] [Related]
6. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
[TBL] [Abstract][Full Text] [Related]
7. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells.
Sun Y; Gu M; Zhu L; Liu J; Xiong Y; Wei Y; Li F
Anticancer Drugs; 2016 Mar; 27(3):183-91. PubMed ID: 26556627
[TBL] [Abstract][Full Text] [Related]
9. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
Wanek T; Traxl A; Bankstahl JP; Bankstahl M; Sauberer M; Langer O; Kuntner C
Nucl Med Biol; 2015 Jul; 42(7):585-9. PubMed ID: 25823393
[TBL] [Abstract][Full Text] [Related]
10. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
11. Influence of bioluminescence imaging dynamics by D-luciferin uptake and efflux mechanisms.
Zhang Y; Pullambhatla M; Laterra J; Pomper MG
Mol Imaging; 2012; 11(6):499-506. PubMed ID: 23084250
[TBL] [Abstract][Full Text] [Related]
12. In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Pparα) at the blood-brain barrier.
Hoque MT; Shah A; More V; Miller DS; Bendayan R
J Neurochem; 2015 Dec; 135(6):1113-22. PubMed ID: 26465636
[TBL] [Abstract][Full Text] [Related]
13. Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain Tumor.
Kim M; Gupta SK; Zhang W; Talele S; Mohammad AS; Laramy J; Mladek AC; Zhang S; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2022 Mar; 50(3):277-286. PubMed ID: 34887255
[TBL] [Abstract][Full Text] [Related]
14. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
[TBL] [Abstract][Full Text] [Related]
15. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.
Zhang Y; Byun Y; Ren YR; Liu JO; Laterra J; Pomper MG
Cancer Res; 2009 Jul; 69(14):5867-75. PubMed ID: 19567678
[TBL] [Abstract][Full Text] [Related]
16. Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).
Do TM; Dodacki A; Alata W; Calon F; Nicolic S; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2016; 49(2):287-300. PubMed ID: 26484906
[TBL] [Abstract][Full Text] [Related]
17. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
[TBL] [Abstract][Full Text] [Related]
18. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.
Xiong H; Callaghan D; Jones A; Bai J; Rasquinha I; Smith C; Pei K; Walker D; Lue LF; Stanimirovic D; Zhang W
J Neurosci; 2009 Apr; 29(17):5463-75. PubMed ID: 19403814
[TBL] [Abstract][Full Text] [Related]
19. An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.
Helms HC; Hersom M; Kuhlmann LB; Badolo L; Nielsen CU; Brodin B
AAPS J; 2014 Sep; 16(5):1046-55. PubMed ID: 24934296
[TBL] [Abstract][Full Text] [Related]
20. Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib.
Goutal S; Gerstenmayer M; Auvity S; Caillé F; Mériaux S; Buvat I; Larrat B; Tournier N
J Control Release; 2018 Dec; 292():210-220. PubMed ID: 30415015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
